{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:40:12Z","timestamp":1789522812495,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Research Program on Emerging and Re-emerging Infectious Diseases"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.08.034","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T06:32:55Z","timestamp":1504247575000},"page":"5388-5395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["The road to a more effective influenza vaccine: Up to date studies and future prospects"],"prefix":"10.1016","volume":"35","author":[{"given":"Kaori","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ainai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.034_b0005","series-title":"Fields virology","author":"Knipe","year":"2007"},{"key":"10.1016\/j.vaccine.2017.08.034_b0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0015","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1056\/NEJMcp0807498","article-title":"Clinical practice. Prevention and treatment of seasonal influenza","volume":"359","author":"Glezen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2672.2001.01492.x","article-title":"A history of influenza","volume":"91","author":"Potter","year":"2001","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0025","first-page":"107","article-title":"The systemic and mucosal immune response of humans to influenza A virus","volume":"146","author":"Murphy","year":"1989","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0264-410X(90)90250-P","article-title":"Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza","volume":"8","author":"Tamura","year":"1990","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.034_b0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/279246a0","article-title":"Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule","volume":"279","author":"Yewdell","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.08.034_b0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tim.2014.01.010","article-title":"Bat-derived influenza-like viruses H17N10 and H18N11","volume":"22","author":"Wu","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0045","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0264-410X(03)00071-9","article-title":"The annual production cycle for influenza vaccine","volume":"21","author":"Gerdil","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.034_b0050","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.284.13.1655","article-title":"Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial","volume":"284","author":"Bridges","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.08.034_b0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1586\/14760584.6.2.193","article-title":"Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic","volume":"6","author":"Hasegawa","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.08.034_b0060","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/cir121","article-title":"Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies","volume":"52","author":"Sui","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.034_b0065","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1172\/JCI41902","article-title":"Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine","volume":"120","author":"Corti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.08.034_b0070","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1073\/pnas.79.15.4800","article-title":"Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes","volume":"79","author":"Krystal","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0075","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/JVI.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0080","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1073\/pnas.0801367105","article-title":"Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies","volume":"105","author":"Kashyap","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0085","doi-asserted-by":"crossref","first-page":"e1000990","DOI":"10.1371\/journal.ppat.1000990","article-title":"Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries","volume":"6","author":"Kashyap","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.08.034_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0095","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1128\/JVI.05397-11","article-title":"Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5","volume":"85","author":"Ohshima","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0100","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/ncomms4614","article-title":"Receptor mimicry by antibody F045\u2013092 facilitates universal binding to the H3 subtype of influenza virus","volume":"5","author":"Lee","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2017.08.034_b0105","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1128\/JVI.00700-11","article-title":"A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin","volume":"85","author":"Krause","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza a subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.08.034_b0115","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1128\/JVI.00178-14","article-title":"Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody","volume":"88","author":"Wyrzucki","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.08.034_b0130","doi-asserted-by":"crossref","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.034_b0135","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","article-title":"Antibody recognition of a highly conserved influenza virus epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.12.014","article-title":"Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV)","volume":"399","author":"Burioni","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.08.034_b0145","doi-asserted-by":"crossref","first-page":"e34415","DOI":"10.1371\/journal.pone.0034415","article-title":"A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses","volume":"7","author":"De Marco","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.034_b0150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0155","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"Whittle","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0160","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.1218256109","article-title":"Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody","volume":"110","author":"Schmidt","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/prot.24745","article-title":"Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage","volume":"83","author":"Xu","year":"2015","journal-title":"Proteins"},{"key":"10.1016\/j.vaccine.2017.08.034_b0170","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chom.2013.06.004","article-title":"An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies","volume":"14","author":"Nakamura","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2017.08.034_b0180","doi-asserted-by":"crossref","first-page":"e1003150","DOI":"10.1371\/journal.ppat.1003150","article-title":"Human monoclonal antibodies broadly neutralizing against influenza B virus","volume":"9","author":"Yasugi","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2017.08.034_b0185","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1073\/pnas.1319058110","article-title":"A common solution to group 2 influenza virus neutralization","volume":"111","author":"Friesen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0190","doi-asserted-by":"crossref","first-page":"14234","DOI":"10.1038\/ncomms14234","article-title":"A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action","volume":"8","author":"Chai","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2017.08.034_b0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0200","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1038\/ncomms8708","article-title":"A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus","volume":"6","author":"Wu","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2017.08.034_b0205","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.virol.2012.09.034","article-title":"Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient","volume":"435","author":"Hu","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.08.034_b0210","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","article-title":"Vaccine-induced antibodies that neutralize group 1 and group 2 influenza a viruses","volume":"166","author":"Joyce","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.08.034_b0215","series-title":"Janeway's immunobiology","author":"Janeway","year":"2012"},{"key":"10.1016\/j.vaccine.2017.08.034_b0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1074-7613(00)00006-6","article-title":"Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities","volume":"13","author":"Xu","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2017.08.034_b0225","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.20052217","article-title":"Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production","volume":"203","author":"Ippolito","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0230","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0235","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2006.02.005","article-title":"The rational design of an AIDS vaccine","volume":"124","author":"Douek","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.08.034_b0240","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0245","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.08.034_b0250","doi-asserted-by":"crossref","first-page":"11686","DOI":"10.1128\/JVI.01694-12","article-title":"A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin","volume":"86","author":"Schneemann","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0255","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1128\/JVI.03004-13","article-title":"Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets","volume":"88","author":"Krammer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0260","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1128\/JVI.03183-13","article-title":"H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge","volume":"88","author":"Krammer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0265","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0270","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1128\/JVI.01715-13","article-title":"Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses","volume":"87","author":"Margine","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0280","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0285","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0290","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The Quest for a Universal Flu Vaccine: Headless HA 2.0","volume":"18","author":"Krammer","year":"2015","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.vaccine.2017.08.034_b0295","first-page":"43","article-title":"Seasonal influenza vaccines","volume":"333","author":"Fiore","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0300","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.4049\/jimmunol.168.6.2930","article-title":"Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines","volume":"168","author":"Asahi","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0305","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7883\/yoken.JJID.2015.560","article-title":"Intranasal inactivated influenza vaccines: a reasonable approach to improve the efficacy of influenza vaccine?","volume":"69","author":"Tamura","year":"2016","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.034_b0310","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1016\/j.vaccine.2012.04.109","article-title":"Mucosal IgA responses in influenza virus infections; thoughts for vaccine design","volume":"30","author":"van Riet","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.034_b0315","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev.mi.37.100183.002525","article-title":"Immunity to influenza in man","volume":"37","author":"Couch","year":"1983","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0320","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/JB.89.1.170-174.1965","article-title":"Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus","volume":"89","author":"Schulman","year":"1965","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0325","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/eji.1830100515","article-title":"Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice","volume":"10","author":"Webster","year":"1980","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0330","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/213612a0","article-title":"Adaptation and growth characteristics of influenza virus at 25 degrees c","volume":"213","author":"Maassab","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.08.034_b0335","unstructured":"CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP): prevention and control of seasonal influenza with vaccines. MMWR, 2009. p. 1\u201352."},{"key":"10.1016\/j.vaccine.2017.08.034_b0340","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vaccine.2015.11.010","article-title":"Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2\u201317 years of age in 2013\u20132014 in the United States","volume":"34","author":"Caspard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.034_b0345","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/infdis\/jiv577","article-title":"Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013\u20132014 in the United States","volume":"213","author":"Gaglani","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.034_b0350","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.38.30350","article-title":"Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?","volume":"21","author":"Penttinen","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.08.034_b0355","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/oxfordjournals.aje.a121170","article-title":"Influenza antibody response following aerosal administration of inactivated virus","volume":"91","author":"Waldman","year":"1970","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0360","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/IAI.40.3.1092-1095.1983","article-title":"Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory","volume":"40","author":"Wright","year":"1983","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.08.034_b0365","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/eji.1830220228","article-title":"Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine","volume":"22","author":"Tamura","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0370","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/S0264-410X(03)00078-1","article-title":"Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia","volume":"21","author":"Ito","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.034_b0375","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","article-title":"Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract","volume":"173","author":"Renegar","year":"2004","journal-title":"J Immunol."},{"key":"10.1016\/j.vaccine.2017.08.034_b0380","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/JVI.75.11.5141-5150.2001","article-title":"Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection","volume":"75","author":"Tumpey","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0385","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jmv.20173","article-title":"Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0390","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.4161\/hv.25458","article-title":"Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults","volume":"9","author":"Ainai","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.08.034_b0395","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0400","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Office of Communication, Training and Manufacturers Assistance, Rockville, Maryland; 2007."},{"key":"10.1016\/j.vaccine.2017.08.034_b0405","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2017.08.034_b0410","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0415","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ni.2067","article-title":"Systems biology of vaccination for seasonal influenza in humans","volume":"12","author":"Nakaya","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0420","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3285","article-title":"Tools to therapeutically harness the human antibody response","volume":"12","author":"Wilson","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0425","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nbt.2782","article-title":"The promise and challenge of high-throughput sequencing of the antibody repertoire","volume":"32","author":"Georgiou","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0430","doi-asserted-by":"crossref","first-page":"171ra19","DOI":"10.1126\/scitranslmed.3004794","article-title":"Lineage structure of the human antibody repertoire in response to influenza vaccination","volume":"5","author":"Jiang","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0435","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chom.2014.05.013","article-title":"Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements","volume":"16","author":"Jackson","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2017.08.034_b0440","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2015.04.028","article-title":"Viral receptor-binding site antibodies with diverse germline origins","volume":"161","author":"Schmidt","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.08.034_b0445","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nm.3743","article-title":"In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire","volume":"21","author":"DeKosky","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0450","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jmb.2006.02.040","article-title":"Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing","volume":"358","author":"Meijer","year":"2006","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0455","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/eji.201343917","article-title":"Single-cell based high-throughput sequencing of full-length immunoglobulin heavy and light chain genes","volume":"44","author":"Busse","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0460","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","article-title":"Antibody landscapes after influenza virus infection or vaccination","volume":"346","author":"Fonville","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.08.034_b0465","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.08.034_b0470","doi-asserted-by":"crossref","first-page":"316ra192","DOI":"10.1126\/scitranslmed.aad0522","article-title":"Immune history profoundly affects broadly protective B cell responses to influenza","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0475","doi-asserted-by":"crossref","first-page":"13463","DOI":"10.1073\/pnas.1312146110","article-title":"Genetic measurement of memory B-cell recall using antibody repertoire sequencing","volume":"110","author":"Vollmers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0480","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nbt.2167","article-title":"A proteomics approach for the identification and cloning of monoclonal antibodies from serum","volume":"30","author":"Cheung","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2017.08.034_b0485","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1073\/pnas.1213737110","article-title":"Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response","volume":"110","author":"Wine","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0490","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1073\/pnas.1317793111","article-title":"Identification and characterization of the constituent human serum antibodies elicited by vaccination","volume":"111","author":"Lavinder","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.08.034_b0495","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/nm.4223","article-title":"Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain","volume":"22","author":"Raymond","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.08.034_b0500","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/nm.4224","article-title":"Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T21:14:47Z","timestamp":1602882887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":100,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17311180"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The road to a more effective influenza vaccine: Up to date studies and future prospects","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}